간장장애 가토에서 베라파밀의 약물동태
Pharmacokinetics of Verapamil in Rabbits with Hepatic Disorder Induced by Carbon Tetrachloride
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
The purpose of this study was to investigate the pharmacokinetic changes of veapamil in rabbits with hepatic disorder induced by carbon tetrachloride. The plasma concentrations of verapamil were increased significantly (p<0.05, in slight group; p<0.01, in moderate and severe group) in all groups of hepatic disorder compared to the control group. Morover, the Cmax in slight (77.9% increase), moderate (110% increase), and severe (174% increase) hepatic disorder groups were significantly (p<0.05, in slight; p< 0.01, in moderate and severe) higher than that in control rabbits. These resulted in significantly (p<0.05, in slight; p<0.01, in moderate and severe) greater area under the plasma concentration-time curve (AUC) in moderate (49.8% increase), moderate (95.0% increase), and severe (144% increase) hepatic disorder groups than that in control rabbits. Hence, the relative bioavailability values were 149, 195, and 244% for slight, moderate, and severe hepatic disorder groups, respectively. This could be due to decrease in metabolism of verapamil in the liver because of suppressed hepatic function in the hepatic disorder groups because verapamil is mainly metabolized in the liver.
참고문헌 (19)
- Fleckenstein A, "Specific pharmacology of calcium in myocardium,cardiac pacemakers,and vascular smooth muscle", 17, pp.149~66 (1977)
- Krikler DM, "Verapamil in the treatment of paroxysmal supraventricular tachycardia", 50, pp.447~53 (1974)
- Gould BA, "The 24-hour ambulatory blood pressure profile with verapamil", 65, pp.22~7 (1982)
- Lewis GR, "The treatment of hypertension with verapamil", 87, pp.351~4 (1978)
- Schomerus M, "Physiological disposition of verapamil in man", 10, pp.605~12 (1976)
- Woodcock BG, "Verapamil disposition in liver disease and intensive-care patients:Kinetics,clearance,and apparent blood flow relationships", 29, pp.27~34 (1981)
- Neugebauer G, "Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog", 12, pp.247~54 (1978)
- verapamil in man, , 1979, 145~8
- Schwartz JB, "An investigation of the cause of accumulation of verapamil during regular dosing in patients", 19, pp.512~6 (1985)
- Freedman SB, "Verapamil kinetics in normal subjects and patients with coronary artery spasm", 30, pp.644~52 (1981)
- Loi CM, "Effect of cimetidine on verapamil disposition", 37, pp.654~7 (1985)
- Johnson LM, "The influence of cimetidine on the pharmacokinetics of the enantiomers of verapamil in the dog during multiple oral dosing", 18, pp.117~123 (1995)
- Ho PC, "Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers", 56, pp.693~698 (2000)
- Fuhr U, "Effects of grapefruit juice and smoking on verapamil concentrations in steady state", 58, pp.45~53 (2002)
- Somogyi A, "Pharmacokinetics,bioavailability and ECG response of verapamil in patients with liver cirrhosis", 12, pp.51~60 (1981)
- Choi JS, "Pharmacokinetics of acebutolol and its main metabolite,diacetolol after oral administration of acebutolol in rabbits with carbon tetrachloride-induced hepatic failure", 25, pp.541~545 (2002)
- Choi JS, "Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure", 25, pp.973~977 (2002)
- Krecic-Shepard ME, "Faster clearance of sustained release verapamil in men versus women:Continuing observations on sex-specific differences after oral administration of verapamil", 68, pp.286~292 (2000)
- Rocci ML Jr, "LAGRAN program for area and moments in pharmacokinetic analysis", 16(3), pp.203~216 (1983)